Showing 181-190 of 3286 results for "".
- AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groupshttps://modernaesthetics.com/news/aad-2026-relabotulinumtoxina-shows-consistent-efficacy-across-age-groups/2486431/A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data
- AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenationhttps://modernaesthetics.com/news/lumenis-launches-trilift-20-for-combined-muscle-and-skin-rejuvenation/2486430/Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address
- AAD 2026: CO2 Laser Resurfacing Linked to Transient Microbiome Shiftshttps://modernaesthetics.com/news/aad-2026-co2-laser-resurfacing-linked-to-transient-microbiome-shifts/2486399/New findings presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, provide insight into dynamic microbiome changes following ablative CO2 laser resurfacing and their relationship to wound healing. In this monocentric, double-blind, rando
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Oral Supplement Shows Gains in Hair Strength, Collagen VIIhttps://modernaesthetics.com/news/aad-2026-oral-supplement-shows-gains-in-hair-strength-collagen-vii/2486396/New data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated a nutraceutical approach to improving hair strength through collagen VII upregulation and mechanical resistance outcomes. The study assessed a daily oral supplement containing turmer
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://modernaesthetics.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to
- New Skin Quality Index Aims to Align Patient–Provider Communication in Aestheticshttps://modernaesthetics.com/news/new-skin-quality-index-aims-to-align-patientprovider-communication-in-aesthetics/2486112/Allergan Aesthetics, an AbbVie company, announced the launch of the Skin Quality Index (SQI), a new framework designed to standardize how patients and health care providers discuss skin quality during aesthetic consultations. The initiative is supported by global research published in Dermato